Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Allergan Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

3 months ended:	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014	Dec 31, 2013	Sep 30, 2013	Jun 30, 2013	Mar 31, 2013	Dec 31, 2012	Sep 30, 2012	Jun 30, 2012	Mar 31, 2012	Dec 31, 2011	Sep 30, 2011	Jun 30, 2011	Mar 31, 2011	Dec 31, 2010	Sep 30, 2010	Jun 30, 2010	Mar 31, 2010
Net earnings (loss)	539,100)	313,400)	418,400)	257,900)	312,300)	300,800)	361,200)	14,400)	325,200)	250,600)	296,400)	230,300)	279,700)	251,000)	248,600)	158,800)	263,100)	(668,700)	241,500)	169,000)
Depreciation and amortization	63,100)	64,000)	60,400)	60,600)	59,500)	60,700)	61,300)	73,100)	65,200)	64,500)	64,200)	62,700)	64,000)	63,500)	62,500)	63,400)	63,200)	61,300)	66,300)	66,300)
Amortization of original issue discount and debt issuance costs	700)	700)	700)	700)	700)	700)	700)	500)	500)	400)	500)	500)	500)	400)	1,300)	7,500)	7,400)	7,100)	7,000)	6,900)
Amortization of net realized gain on interest rate swap	(3,800)	(3,800)	(3,700)	(3,700)	(3,600)	(3,600)	(3,600)	(3,600)	(3,500)	(3,500)	(400)	(300)	(300)	(300)	(400)	(300)	(300)	(300)	(400)	(300)
Deferred income tax provision (benefit)	(66,400)	(17,300)	—)	3,900)	(58,100)	(32,800)	(12,600)	(88,700)	(47,700)	(28,300)	(9,700)	(2,600)	(18,100)	(6,600)	(17,600)	(26,600)	(98,500)	(144,700)	6,200)	(12,100)
Acquired in-process research and development technology	—)	—)	(10,000)	10,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
(Gain) loss on disposal and impairment of assets	21,100)	8,000)	500)	200)	1,900)	2,700)	700)	500)	700)	5,000)	(100)	100)	2,100)	—)	(600)	(1,500)	5,800)	11,400)	300)	400)
Unrealized (gain) loss on derivative instruments	(18,200)	(34,100)	10,900)	4,200)	(6,100)	7,600)	(10,600)	(1,300)	100)	7,100)	(4,400)	12,500)	900)	(16,800)	(2,100)	6,900)	600)	15,200)	(8,900)	700)
Expense of share-based compensation plans	52,600)	41,000)	31,400)	34,700)	29,800)	27,800)	27,800)	29,000)	29,400)	26,900)	26,800)	26,000)	22,000)	22,400)	21,100)	20,800)	20,500)	18,100)	17,100)	18,200)
Loss on sale of discontinued operations	—)	—)	—)	—)	3,300)	58,700)	—)	346,200)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Legal settlement	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(594,700)	609,900)	—)	—)
Impairment of intangible assets and related costs	—)	—)	—)	—)	11,400)	—)	—)	—)	22,300)	—)	—)	—)	—)	4,300)	—)	16,100)	—)	369,100)	—)	—)
(Income) expense from changes in fair value of contingent consideration	400)	(18,900)	3,700)	(300)	65,900)	1,500)	(2,500)	5,800)	(10,400)	2,400)	12,800)	600)	9,600)	—)	2,300)	—)	7,900)	—)	—)	—)
Provision for losses on trade receivables in Venezuela	—)	37,300)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Restructuring charges	38,100)	185,500)	(1,500)	24,300)	600)	600)	—)	4,300)	1,000)	3,800)	900)	—)	—)	(100)	100)	4,600)	(500)	100)	100)	600)
(Gain) loss on investments, net	3,100)	—)	—)	—)	—)	—)	—)	3,700)	—)	—)	—)	—)	2,700)	(500)	(900)	—)	—)	—)	—)	—)
Pension and other post-retirement benefit plans settlements and curtailments	12,100)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Non-cash items included in net earnings (loss)	102,800)	262,400)	92,400)	134,600)	105,300)	123,900)	61,200)	369,500)	57,600)	78,300)	90,600)	99,500)	83,400)	66,300)	65,700)	90,900)	(588,600)	947,200)	87,700)	80,700)
Trade receivables	28,500)	14,300)	(55,000)	(103,500)	33,800)	19,600)	(40,200)	(152,800)	116,800)	1,100)	(28,100)	(124,100)	(23,900)	(1,900)	(65,600)	(14,200)	(60,000)	36,500)	(59,500)	11,600)
Inventories	(18,900)	(14,100)	1,400)	(12,200)	(4,300)	(3,000)	(19,700)	100)	4,900)	(2,200)	(5,500)	(4,500)	(4,600)	(14,200)	1,500)	(6,700)	(6,500)	(7,500)	11,500)	(3,100)
Other current assets	(13,800)	(13,700)	(2,600)	6,800)	(24,000)	(5,500)	20,900)	7,800)	3,400)	(20,400)	(7,300)	8,300)	(6,700)	(13,900)	(7,800)	(4,700)	4,200)	(11,500)	37,500)	(22,900)
Other non-current assets	(16,200)	3,300)	(12,100)	(4,700)	(7,300)	400)	(5,300)	(3,300)	(2,400)	49,900)	2,500)	(5,900)	—)	(6,900)	(1,100)	(5,400)	(8,100)	(8,000)	200)	(2,700)
Accounts payable	7,000)	(21,100)	(7,400)	23,400)	14,800)	29,000)	22,100)	(28,500)	19,100)	9,600)	(500)	4,500)	12,800)	(3,100)	(7,400)	(21,600)	32,000)	(1,200)	(56,300)	34,100)
Accrued expenses	12,900)	67,400)	82,400)	(46,800)	52,100)	76,900)	47,500)	(66,300)	(40,900)	80,800)	51,800)	(18,600)	17,200)	19,100)	56,500)	(53,700)	1,000)	31,900)	60,800)	(59,300)
Income taxes	9,500)	(19,100)	(30,900)	(83,500)	44,500)	34,500)	22,500)	(36,600)	14,000)	4,300)	22,900)	11,200)	18,100)	30,000)	(51,800)	(16,100)	3,900)	(22,200)	22,500)	(21,800)
Other liabilities	43,300)	1,700)	(13,300)	(6,200)	(11,900)	2,400)	11,300)	15,300)	2,200)	9,700)	6,600)	8,200)	4,400)	(6,200)	4,500)	10,900)	2,000)	13,100)	(7,900)	(12,300)
Changes in operating assets and liabilities	52,300)	18,700)	(37,500)	(226,700)	97,700)	154,300)	59,100)	(264,300)	117,100)	132,800)	42,400)	(120,900)	17,300)	2,900)	(71,200)	(111,500)	(31,500)	31,100)	8,800)	(76,400)
Net cash provided by operating activities	694,200)	594,500)	473,300)	165,800)	515,300)	579,000)	481,500)	119,600)	499,900)	461,700)	429,400)	208,900)	380,400)	320,200)	243,100)	138,200)	(357,000)	309,600)	338,000)	173,300)
Purchases of short-term investments	—)	(159,900)	(445,600)	(664,300)	(381,100)	(459,700)	(134,800)	(50,000)	(160,600)	(199,900)	(284,800)	(219,900)	(179,900)	(66,400)	(174,900)	(149,900)	(324,800)	(499,300)	—)	—)
Purchase of non-marketable equity investment	(10,300)	—)	—)	(10,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Acquisitions, net of cash acquired	—)	(67,500)	—)	—)	—)	—)	(20,700)	(871,400)	(346,100)	—)	—)	(3,100)	(2,500)	(91,900)	(7,000)	—)	—)	(6,100)	—)	(63,700)
Additions to property, plant and equipment	(58,500)	(75,500)	(63,500)	(46,400)	(74,500)	(35,000)	(38,700)	(23,700)	(45,200)	(40,800)	(34,200)	(23,100)	(43,200)	(29,100)	(29,200)	(17,100)	(52,500)	(20,300)	(17,500)	(12,500)
Additions to capitalized software	(6,400)	(4,000)	(5,000)	(3,600)	(3,200)	(3,000)	(2,900)	(2,700)	(6,400)	(3,800)	(2,000)	(1,700)	(3,300)	(1,800)	(2,800)	(3,300)	(3,100)	(3,500)	(3,800)	(2,900)
Additions to intangible assets	—)	(5,000)	(10,000)	—)	—)	—)	—)	(300)	—)	(600)	(3,500)	—)	—)	(300)	—)	—)	(22,400)	(18,500)	—)	—)
Contractual purchase price adjustment to prior acquisition	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(1,700)
Proceeds from maturities of short-term investments	219,600)	410,900)	719,800)	465,600)	302,700)	119,900)	—)	260,600)	179,900)	224,900)	329,800)	50,000)	66,400)	299,800)	124,800)	649,300)	75,000)	—)	—)	—)
Proceeds from sale of business	—)	—)	—)	1,800)	42,700)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Proceeds from sale of equity investments	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	500)	500)	900)	—)	—)	—)	—)	—)
Proceeds from sale of property, plant and equipment	200)	100)	100)	100)	100)	300)	—)	100)	500)	700)	300)	300)	100)	300)	600)	200)	400)	—)	—)	—)
Net cash (used in) provided by investing activities	144,600)	99,100)	195,800)	(256,800)	(113,300)	(377,500)	(197,100)	(687,400)	(377,900)	(19,500)	5,600)	(197,500)	(161,900)	111,100)	(87,600)	479,200)	(327,400)	(547,700)	(21,300)	(80,800)
Repayments of convertible borrowings	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(808,900)	—)	—)	—)	—)	—)
Dividends to stockholders	(14,900)	(14,900)	(14,900)	(14,900)	(14,800)	(14,900)	(14,800)	(14,900)	(15,000)	(15,000)	(15,200)	(15,200)	(15,300)	(15,200)	(15,300)	(15,300)	(15,200)	(15,100)	(15,200)	(15,100)
Payments to acquire treasury stock	(4,100)	(1,100)	(436,000)	(398,000)	(1,400)	(200)	(700)	(648,400)	(185,700)	(174,300)	(332,100)	(216,900)	(87,700)	(75,000)	(136,100)	(162,900)	(87,100)	(63,200)	(76,100)	(59,600)
Purchase of noncontrolling interest in a subsidiary	—)	—)	—)	—)	(18,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Payments of contingent consideration	—)	—)	(2,600)	(7,600)	(50,100)	—)	(1,000)	(10,100)	—)	—)	—)	(5,100)	—)	—)	(100)	(2,900)	—)	—)	—)	—)
Net borrowings (repayments) of notes payable	16,300)	(5,100)	(100)	5,400)	18,400)	(14,400)	(5,600)	8,400)	8,000)	(1,600)	(45,300)	3,800)	5,000)	2,800)	14,700)	8,200)	9,600)	5,400)	(4,900)	(3,500)
Sale of stock to employees	132,700)	52,500)	118,200)	217,600)	19,200)	19,500)	28,400)	112,200)	92,500)	26,800)	40,000)	87,100)	58,300)	27,500)	97,800)	80,400)	143,400)	33,800)	20,800)	36,000)
Excess tax benefits from share-based compensation	53,400)	16,200)	38,900)	59,000)	4,100)	1,800)	1,000)	30,800)	21,200)	3,500)	6,100)	14,900)	16,900)	3,100)	13,100)	4,600)	22,400)	3,700)	1,000)	—)
Debt issuance costs	—)	—)	—)	—)	—)	—)	(1,100)	(3,700)	—)	—)	—)	—)	—)	—)	—)	—)	(100)	(6,000)	—)	—)
Proceeds from issuance of senior notes, net of discount	—)	—)	—)	—)	—)	—)	—)	598,500)	—)	—)	—)	—)	—)	—)	—)	—)	—)	648,000)	—)	—)
Net cash provided by (used in) financing activities	183,400)	47,600)	(296,500)	(138,500)	(42,600)	(8,200)	6,200)	72,800)	(79,000)	(160,600)	(346,500)	(131,400)	(22,800)	(56,800)	(834,800)	(87,900)	73,000)	606,600)	(74,400)	(42,200)
Effect of exchange rate changes on cash and equivalents	(21,600)	(20,300)	2,000)	(1,300)	400)	9,000)	(5,400)	(8,000)	3,800)	4,700)	(11,500)	5,600)	(1,600)	(19,000)	5,000)	10,100)	(700)	15,200)	(12,400)	(7,700)
Net increase (decrease) in cash and equivalents	1,000,600)	720,900)	374,600)	(230,800)	359,800)	202,300)	285,200)	(503,000)	46,800)	286,300)	77,000)	(114,400)	194,100)	355,500)	(674,300)	539,600)	(612,100)	383,700)	229,900)	42,600)

The financial data over the analyzed periods exhibits a mix of volatility and growth across various categories, reflecting fluctuations in earnings, cash flows, and expense components.

Net Earnings (Loss): The net earnings show considerable variability, with a notable loss in September 2010 (-668,700) following positive results in the prior quarters. Recovery is observed in subsequent periods with generally positive earnings, especially strong increases seen from mid-2013 to 2014, culminating in a peak of 539,100 in December 2014.
Depreciation and Amortization: This expense remains relatively stable throughout the periods, ranging mostly between 59,500 and 73,100, indicating consistent capital asset utilization and amortization practices.
Amortization of Original Issue Discount and Debt Issuance Costs: Values show minor fluctuations but generally stay low, around 400 to 7,500, without indicative spikes that would suggest unusual financing activities.
Unrealized Gain/Loss on Derivative Instruments: There is significant volatility in this item, with swings between positive and negative values, demonstrating sensitivity to market changes and the impact of hedging or derivative activities. For instance, large negative values appear in mid-2012 and late 2014 (-34,100 and -18,200 respectively), indicating losses on derivatives.
Expense of Share-Based Compensation Plans: An upward trend is observed from 18,200 in early 2010 to 52,600 by the end of 2014, signifying increased employee compensation costs, possibly linked to company growth or incentives.
Legal Settlements and Impairments: Irregular but significant legal settlement entries appear in mid-2010 and early 2011, including a major settlement-related charge of 609,900 in June 2010 followed by a reversal (-594,700) in September 2010. There are periodic impairments of intangible assets, for example, a substantial impairment of 369,100 in September 2010.
Restructuring Charges: Charges vary widely, with some large spikes registered such as 185,500 in September 2014, indicating periodic restructuring efforts likely aimed at operational realignment or cost management.
Operating Assets and Liabilities Changes: These fluctuate considerably but tend to have large magnitude changes, both positive and negative, reflecting active working capital management. For instance, large negative changes in March 2013 (-264,300) contrast with significant positive changes in September 2013 (154,300) and December 2013 (97,700).
Net Cash Provided by Operating Activities: Operating cash flows generally trend upward, despite some quarters showing negative cash flow (notably December 2010 and March 2013). Peaks in operating cash flows appear in 2013 and 2014, reaching up to 694,200 in the last reported quarter.
Investing Activities: Investing cash flows demonstrate substantial outflows in several quarters, particularly related to acquisitions and purchases of short-term investments, such as peaks in acquisitions (-871,400 in March 2013) and investments purchases (-664,300 in March 2014). However, some quarters show positive investing cash inflows, mainly due to proceeds from maturities and sale of assets.
Financing Activities: Financing cash flows are marked by large swings, with sporadic high inflows such as 606,600 in September 2010 related to debt issuance, countered by significant outflows associated with repayments and stock repurchases. Payments to acquire treasury stock increase dramatically starting late 2012, peaking at -648,400 in March 2013.
Cash and Equivalents: The net increase in cash and equivalents is highly variable, with substantial increases in some periods (e.g., 1,000,600 in December 2014) and sharp decreases in others (e.g., -612,100 in December 2010 and -503,000 in March 2013), reflecting the combined effects of the company’s operating, investing, and financing activities as well as exchange rate effects.
Working Capital Components: Trade receivables and inventories show volatile values with no consistent trend, indicating varying sales levels or inventory management practices. Accounts payable and accrued expenses also display substantial fluctuations, highlighting dynamic supplier and expense management.

In summary, the data highlights periods of significant financial adjustments including earnings volatility, major legal and restructuring charges, active capital investments, and substantial share repurchases. Operating cash flow trends are positive overall, supporting growth despite intermittent negative cash flow quarters. The company appears to engage in frequent financial restructuring and investment activities, impacting overall liquidity and capital structure across the examined periods.

Download chart

Allergan Inc. (NYSE:AGN.)

Cash Flow Statement Quarterly Data

Cash Flow Statement
Quarterly Data